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 1 
Cryptococcal meningitis screening and community-based early adherence support 
reduces all-cause mortality among HIV-infected people initiating antiretroviral 
therapy with advanced disease: a randomised-controlled trial in Tanzania and 
Zambia.  
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 2 
Background. Mortality rates of HIV-infected Africans starting antiretroviral therapy are 
high, particularly among those with advanced disease. We assessed the impact of a short 
period of community support to supplement clinic-based services combined with serum 
cryptococcal antigen screening.  
Methods We undertook a randomised trial in urban clinics in Dar es Salaam, Tanzania 
and in Lusaka, Zambia. 1999 HIV-infected patients were randomised individually to 
either the standard clinic-based care supplemented with community support (CCS) or 
standard clinic based care alone. CCS comprised screening for serum cryptococcal 
antigen combined with antifungal therapy for those testing antigen positive, weekly 
home visits for the first 4 weeks on ART by lay-workers to provide support, and in 
Tanzania alone, re-screening for TB at 6-8 weeks after ART initiation. Randomisation 
was stratified by country and clinic and done in permuted block sizes of 10 by an 
independent statistician. The trial was integrated into normal service delivery. All adult 
patients with CD4-cell counts <200 cells/ μL who reported that they had not been on 
ART previously and who did not need immediate hospital admission were enrolled 
between February 2012 and September 2013. Follow-up ended on 30th September 
2014. The primary endpoint was all-cause mortality. Analyses were by intention to 
treat. This trial is registered at http://isrctn.org, number (ISCRTN 20410413). 
Findings 1001 patients were assigned randomly to CCS and 998 to standard care. Over 
a 12-month follow-up, 25 (2.5%) in the CCS arm and 24 (2.4%) in the standard care arm 
were lost to follow-up and the number of deaths was 134(13.4%) and 180 (18.1%) 
respectively. The mortality rate was 28% (95% CI 10%, 43%) lower in the CCS arm than 
in standard care (p=0.004). In the CCS arm, 38 (3.9%), were serum cryptococcal antigen 
positive and their mortality rate was 2.90 (95% CI 1.60, 5.26) higher than that among 
serum antigen negatives after adjusting for CD4 count, age, sex and country. 147 
participants in Tanzania who did not have active TB at enrolment were re-screened a 
median of 58 (interquartile range 44, 72) days after enrolment by GeneXpert and 8 
(5.4%, 95% CI 1.8, 9.0%) were newly diagnosed with TB. The full intervention cost was 
USD 67.26 (95% CI 64.0, 70.52) per person in Tanzania and USD 54.19 (95% CI 52.94, 
55.43) per person in Zambia. 
Interpretation. A simple low-cost intervention comprising a short period of home 
support combined with screening for cryptococcal meningitis reduces mortality 
substantially among HIV-infected with advanced disease.  
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INTRODUCTION 
 
About 10 million people in Africa are now on antiretroviral therapy (ART) 1. Mortality 
rates of Africans during the first year on ART are higher than among Europeans, 
particularly during the first few weeks 2. In addition, in Africa, there is substantial 
mortality 3-5 and loss-to-follow-up 6, 7 during the pre-treatment period between a 
patient’s first presentation to clinic and ART initiation. About a third of Africans still 
initiate ART with advanced disease 8-10 and they have a very high disease burden.  
 
Tuberculosis and cryptococcal meningitis account for the majority of the deaths among 
HIV-infected people presenting at health facilities in Africa 11-14. For tuberculosis, the 
median diagnostic delay is about 2 months overall 15 and diagnosis among HIV co-
infected people presenting with advanced HIV disease is particularly challenging 16. In 
autopsy studies, tuberculosis has been detected in over 50% of HIV-infected adults 17. 
Cryptococcal meningitis occurs mostly among those with CD4 count<100 /μl 18 and has 
an associated mortality rate of between 25% to 50% in clinical trials and well-
functioning clinical settings 14, 19, 20. The mortality associated with  cryptococcal 
meningitis has remained high in some settings despite increased access to ART 21, 22.  
 
The biggest challenge facing health care delivery in Africa is the severe shortage of 
qualified health care workers, particularly doctors 23. In a cluster-randomised trial, it has 
been shown that home-based care delivered by trained lay-workers was as effective as 
standard clinic-based care in a predominately rural setting where access to clinics was 
difficult 24, 25.  
 
In this trial, we evaluated a short period of community-based support provided to HIV-
infected individuals who presented at urban health centres with advanced disease 
combined with enhanced screening for tuberculosis and cryptococcal meningitis. 
 
 
METHODS  
 
Study settings and patients 
 
We undertook the trial in 6 public clinics; 3 in Dar es Salaam, Tanzania, and 3 in Lusaka, 
Zambia (ISCRTN 20410413). These were busy clinics serving urban and peri-urban 
populations. They were run largely by clinical officers and nurses and were seeing 
between 100 and 300 patients daily. The trial was done in conditions similar to those of 
actual health services, with the clinical staff working in government clinics responsible 
for service delivery. No additional clinical staff were employed for the conduct of the 
trial. Interviewers employed by the research programme were based at the clinics and 
interviewed patients in-between their usual consultations, in a separate dedicated 
research office.  
 
The interviewers sought consent and collected trial data, including on the socio-
economic aspects. Participants were interviewed at every clinic visit. Patient 
information sheets, consent forms and questionnaires were translated into the local 
language (Swahili in Tanzania, and Bemba and Nyanja in Zambia), then back-translated 
into English by a second person, and cross-checked by a third person. The translators 
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were not involved with the trial. Clinical data were transcribed onto forms from patient 
notes.  An on-site quality control officer checked the completeness and internal 
consistency of the data collected from each patient while the patient was still in clinic. 
No incentives or re-imbursements were provided to the patients.  
 
Recruitment to the trial began in February 2012 and ended in September 2013. Each 
participant was followed for up to 12 months; follow-up ended on 30th September 
2014. When the trial began, consecutive HIV-infected individuals were invited to join the 
trial provided they were over 18 years old, presented with a CD4 count <100 cells /μl, 
lived in the trial clinic catchment population, were able to communicate with trial staff 
and reported that they had not been on ART previously.  Those who needed immediate 
hospital admission were excluded. The trial enrolment criteria were changed 
subsequently to include those presenting with CD4 count <200 cells / μl in view of slow 
recruitment and in view of the fact such patients are still at high risk of mortality. This 
change was implemented in September 2012 in Zambia and in December 2012 in 
Tanzania.  
 
The trial protocol was approved by the ethics committee of the London School of 
Hygiene and Tropical Medicine, Ethics and Research Science (ERES Converge) 
committee in Zambia and the National Health Research Ethics Sub-Committee 
(NatHREC) of Medical Research Coordinating Committee (MRCC) in Tanzania.  
 
 
Study design 
 
This was an open-label randomised controlled trial. The primary endpoint was all-cause 
mortality. Prior to the trial, HIV-infected patients were required to attend clinic on at 
least 3 occasions over a 4-6 week period prior to ART initiation in order to receive 
information and counselling on ART adherence; this practice is common in many well-
functioning African clinics 26-28. We streamlined clinic procedures in order to ensure 
rapid ART initiation within two short-spaced visits. HIV-infected patients presenting to 
one of the trial clinics for the first time were asked to provide blood for CD4 count 
testing and asked to return to clinic within 4-7 days; those who did not and had CD4 
count <200 cells /μl were phoned by clinic staff and encouraged to return. At the second 
visit, patients were initiated on ART unless there were clinical grounds to delay. They 
were invited to join the trial if they fulfilled the eligibility criteria. All trial participants 
were offered screening for tuberculosis (TB) using the GeneXpert®MTB/RIF assay 
(Cepheid, Sunnyvale, USA) (hereon referred to as Xpert) 29. Sputum was requested 
irrespective of any symptoms. In Tanzania, the test was usually done within 24 hours 
and in Zambia within 48 hours. Those diagnosed were initiated on anti-TB treatment, 
and if possible, ART initiation was delayed by 2 weeks in accordance with local 
guidelines. The research programme purchased Xpert cartridges and facilitated access 
to testing machines but the testing and management of equipment and supplies was 
done by health care staff in order to maintain close to normal health service conditions.  
 
Randomisation 
Participants were randomised individually 30 to either the standard clinic-based care 
supplemented with community support (referred hereon as clinic plus community 
support), or to standard clinic-based care arm alone (referred hereon as standard care). 
 5 
Randomisation was stratified by country and clinic and done in permuted block sizes of 
10 by an independent statistician using Stata 12.1. An independent researcher placed 
the trial arm codes, together with a code for the patient identifier, into separate sealed 
envelopes that were opened sequentially by the study participants following 
recruitment.   
 
 
Models of care 
 
In the standard care arm, patient management and schedule of clinic visits followed 
national guidelines. In the clinic plus community care arm, these services were 
supplemented during the first weeks following ART initiation, as follows: i) participants 
were screened at enrolment for cryptococcal meningitis using a novel serum antigen 
test and offered antifungal treatment if they were antigen positive, ii) participants had 
weekly visits for four weeks by trained lay-workers either to their homes or nearby 
locations and iii) in Tanzania alone, re-screening for TB using Xpert was done after 
about six weeks on ART among participants in whom TB was not diagnosed at 
enrolment.  
 
Screening for cryptococcal antigenaemia was done using a serum rapid antigen test 
(IMMY, Norman OK, USA). This was done at the point-of-care and generally provided 
results within 15 minutes. Participants who were serum antigen negative were initiated 
on ART immediately. Those who were positive were advised to have a lumbar puncture 
done and referred to hospital for the procedure if they agreed. If the lumbar puncture 
showed cryptococcal antigen in the cerebrospinal fluid (CSF), then the participant was 
started on amphotericin B at a dose of one mg/kg/day for 14 days followed by oral 
fluconazole at 400mg/day for at least 8 weeks; if they declined lumbar puncture or if 
this was negative, then the patient was initiated on oral fluconazole at 800mg/day for 2 
weeks followed by 400mg/day for 8 weeks. In accordance with national clinical 
guidelines at the time, ART was delayed by two weeks among participants who were 
serum cryptococcal antigen positive.  
 
The lay-workers delivered the ART, provided adherence support and monitored the 
participants for signs and symptoms of drug toxicity or disease progression using a 
checklist. They referred participants to the clinic if this was indicated and phoned a 
clinician or nurse based at the clinic when they were uncertain about referral. Most lay-
workers had degree qualifications or college diplomas and received a small salary lower 
than a nurse in each country. They had 2 weeks of classroom training at the beginning 
followed by on-the-job training. The training package included simple definitions of 
major infections, adherence support, side effects and research ethics. They were also 
given information on the workings of the health system.  
 
The lay-workers travelled mostly on public transport and occasionally used motorbike 
taxis or bicycles. They often met the participant for the first time at the clinic and 
arranged a meeting point, either at the patient’s home or a location nearby. Lay-workers 
telephoned the participant the day before a home visit to confirm the visit. If the 
participant was not seen at the arranged time, the lay-worker visited the following day; 
if the participant was not present again, then a note was left for the participant to come 
to clinic.  
 6 
 
Follow-up of study participants 
Survival status of participants was established from clinic attendance records. Those 
who dropped out of care were telephoned or visited at home. Towards the end of the 
study, we did a follow-up survey that involved visiting trial participants who had moved 
out of the area.  
 
Statistical analyses.  
 
A sample size target of 2030 participants in both arms was chosen. We envisaged that 
this would provide 90% power to detect a 40% difference in mortality rates between 
the two arms assuming 10 deaths per 100 person-years in the standard care arm (at the 
5% two-sided significance level).  
 
Analyses were done as intention-to-treat. Survival rates in the two trial arms were 
compared using a Kaplan-Meier survival curves and a log-rank test. To assess the 
robustness of the findings, we conducted 3 further a priori analyses comparing mortality 
rates between the two arms: i) we used Poisson regression to adjust the mortality rate 
ratios for study site, age, sex, and baseline CD4 count, ii) we assumed that all 
participants lost to follow-up had died at the time of loss to follow-up, iii) we assumed 
that all participants who were lost to follow-up in the first 28 days after ART initiation 
had died at the time that they were lost to follow-up, but that participants lost to follow-
up more than 28 days after ART initiation had survived to the end of the year.  
 
We compared the proportion of patients retained on ART, the prevalence of 
adherence (not having missed a pill in the previous 28 days) and the rate of first 
hospital admission between arms using either risk or rate ratios with 95% confidence 
intervals. Poisson regression was used to compare the mortality rate between 
cryptococcal antigen positive and negative participants adjusting for baseline CD4 
count, age sex and country. 
 
Health service costs: Incremental health service costs of the intervention were estimated 
based on resource use at the individual patient level. Patient resource use was tracked 
through trial records.  An ingredients approach was used to cost the resources used 
based on primary data collection in Tanzania.  A combination of primary and secondary 
cost data were used in Zambia 31, 32. Details of the costing sources are described in the 
appendix. The intervention costs comprised the direct costs of implementing the clinic 
plus community support intervention over and above standard care. One-way sensitivity 
analyses were done to accommodate the uncertainty around the price of lay-worker 
time the number of home visits that they could undertake, and the possible future price 
falls of the serum cryptococcal antigen test.  The lay-worker salary paid by the trial was 
below that of junior nurse. Costs are presented in US dollars, 2012 prices. All analyses 
were done using Stata 13.1. 
 
 
RESULTS  
 
Participant characteristics 
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Figure 1 shows the trial profile.  Twenty-six (0.8%) patients declined to join the trial and 
1999 were randomised either to the clinic plus community support (n=1001) or the 
standard care arm (n=998). The characteristics of the two groups were well balanced 
(Table 1). Overall, median (IQR) CD4 count/μl was 52 (20, 89) in Tanzania and 77 (40, 
128) in Zambia. In Zambia 1001/1129 (88.7%) were treated by the single pill fixed-dose 
combination comprising tenofovir (TDF), emtricitabine (FTC) and efavirenz (EFV); in 
Tanzania, ART varied but almost 60% were receiving  tenofovir (TDF), emtricitabine 
(FTC) or lamivudine (3TC) and efavirenz (EFV). Overall, the median time (IQR) from 
first presentation to clinic for assessment of ART eligibility to ART initiation was 14 (9, 
20) days in the clinic plus community support arm compared with 14 (8, 20) days in the 
standard care arm (p=0.8).  
 
Frequency of lay-worker visits in the clinic plus community support arm.  
In the clinic plus community-support arm, lay-workers met 547 (62.9%) of study 
participants in the home, 273 (31.4%) at a location very near the participant’s home and 
50 (5.8%) at other locations including another family member’s home and the 
workplace. 660 (65.9%) of the participants received all 4 scheduled home visits, 139 
(13.9%) had 3 visits, 64 (6.4%) had two visits, 60 (6.0%) had a single visit and 78 
(7.8%) had no visits. Of the 341 participants who had not received all 4 visits, 108 
(31.7%) had died, were hospitalised or had withdrawn from care. Only 4 participants 
refused home visits because they had not disclosed their HIV status to household 
members and the contact details were incorrect in a further 14 participants.  
 
Detection of new cases of tuberculosis at baseline and follow-up 
Overall 325/1999 (16.3%) participants presented while already on anti-TB treatment 
(Table 2). Sputum was obtained spontaneously from 1372 /1674 (82.0%) of the 
remainder and 189/1674 (11.3%) were newly diagnosed with TB at enrolment; 69 
(36.5%) of these did not report a cough. In 97/189 (51.3%), the TB diagnosis was made 
on the basis of sputum smear and the clinical picture. An additional 88 (46.6%) were 
diagnosed primarily on the basis of the Xpert result and 4 (2.1%) on the basis of culture. 
The median time between first presentation and initiation of anti-TB treatment was 19 
(IQR 10-37) days. 
 
In Tanzania (where re-screening of TB by Xpert was implemented), 114 (26.3%) of the 
434 in the clinic plus community care arm either presented or were diagnosed with TB 
at baseline, 29 died or were lost to follow-up within 60 days, leaving 291 who should 
have had a repeat screen for TB. Only 147/291 (50.5%) were re-screened, which was 
done a median of 58 (IQR 44, 72) days from first presentation to clinic. Eight of 147 
(5.4%, 95% CI 2.4 to 10.4) tested Xpert positive, giving an incidence rate 27.7 (95% CI 
12.0, 54.6) per 100 person-years years between the start of the trial and re-screening.  
 
 
Prevalence of cryptococcal serum antigen positivity at baseline. 
Overall 38/ 985 (3.9%) in the clinic plus community support arm were serum 
cryptococcal antigen test positive; this was 33/717 (4.6%) among those with CD4 
count<100 cells /μl and 5/268 (1.9%) among those with CD4 count between 100 and 
200 cells /μl.  Sixteen participants were not tested because of a stock-out of test kits.  
Only 9/38 (23.7%) cryptococcal serum antigen positive individuals agreed to have a 
lumbar puncture done despite medical advice. Five of the 9 were in Tanzania, and were 
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found to be CSF negative, and 4 were in Zambia, 3 of whom tested positive for 
cryptococcal antigen in their CSF and one tested negative. Thus, only 3 of 985 (0.3%, 
95% CI 0.06, 0.8%) were confirmed with cryptococcal meningitis using the trial 
screening protocol. All 3 had CD4 count<100 cells//μl and were initiated on 
amphotericin-B within 24 hours. Of the other 35 serum cryptococcal antigen positive 
participants, 34 were initiated on fluconazole monotherapy a median of 1(IQR 1, 3) days 
after the test and one refused antifungal treatment.  
 
 
Impact of the intervention on all-cause mortality and other outcomes. 
Survival status was determined for 1950/1999 (97.5%) participants at 12 months; the 
remainder 49 (2.5%), who were equally distributed between the trial arms, could not be 
traced (Figure 1). Table 3 shows the death rates by trial arm. Overall 134/1001 (13.4%) 
individuals in the clinic plus community care arm died compared with 180/998 (18.0%) 
in the standard care arm. The mortality rate was 28.4% (95% CI 10.5%, 42.8%) lower in 
the clinic plus community care arm than in the standard care arm (p=0.004) and the 
effect was observed consistently in Tanzania and Zambia. The reduction in mortality 
was unchanged after sensitivity analyses. Overall 107 (34.1%) of the deaths occurred 
within one month of follow-up. In stratified analyses, among those who had presented 
with CD4 count <50 /μl and those who presented with CD4 count ≥ 50 /μl, the mortality 
rates were 19.8% (95% CI: -8.6, 40.7%) and 35.3% (95% CI: 9.8, 53.6%) lower in the 
clinic plus community care arm than in the standard care arm respectively (Figure 2).  
 
Retention: the number alive and retained in care over the 12 month period was 842 
(84.1%) in the clinic plus community support arm compared with 794 in the standard 
care arm (79.6%) (risk ratio 1.06, 95% CI 1.01, 1.10; p=0.008). 
 
Admissions: 77/1001 (7.7%) individuals in clinic plus community support arm 
compared with 73 /998 (7.3%) in the standard care arm were admitted at least once 
(rate ratio 1.02, 95 %CI 0.74, 1.41; p=0.82) (Table 3). The median (IQR) times to the first 
admission were 24 (11, 43) and 26 (14, 67) days respectively in the two arms.  
 
Adherence: reported perfect adherence (i.e. not missing a single pill) during the last 28 
days was about 90% in both the trial arms at 6 and 12 months following enrolment 
(Table 4).  
 
Mortality rates among those with cryptococcal meningitis co-infection 
The mortality was markedly higher among serum cryptococcal antigen positive 
participants than negatives (Figure 2, Table 5). Two of the three individuals in whom 
cryptocococcal antigen was detected in the CSF died (on days 14 and 45) and the third 
survived. All 3 had CD4 count<100/μl. If these 3 are excluded and the analysis restricted 
to participants with CD4 count<100/μl at enrolment, then 9/30 (30%) died. The 
mortality rate in this group was 43.3 (95% CI 22.5, 83.3) deaths per 100 person years 
and the rate ratio (in relation to serum antigen negative) was 2.54 (95% CI 1.29, 5.03) 
unadjusted and 2.53 (95% CI: 1.27, 5.01) after adjusting for CD4 count, age, sex, country 
 
Costs associated with the delivery of the intervention  
The mean number of home visits per participant was 2.89 (95% CI: 2.76, 3.08) in 
Tanzania and 3.51 (95% CI: 3.42, 3.66) in Zambia at a cost of USD 14.74 and USD 13.03 
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per visit, respectively.  The mean per participant costs of the lay-worker component for 
Tanzania and Zambia were USD 42.60 (95% CI: 40.71, 44.49) and USD 45.77 (95% CI: 
44.56, 46.97), respectively.  The full intervention cost was USD 67.26 (95% CI: 64.0, 
70.52) per person in Tanzania, including the second Xpert test and USD 54.19 (95% 
CI:52.94, 55.43) per person in Zambia where the second Xpert test was not 
implemented.  
 
In the sensitivity analysis, halving the price of the serum cryptococcal antigen test 
results in a cost per person of USD 65.01 (95% CI: 61.75-68.27) and USD 52.00 (95% CI: 
50.76-53.24) in Tanzania and Zambia respectively.  Increasing the number of home 
visits by lay-workers to 4 per patient per day reduces the intervention cost to USD 40.99 
(CI: 38.48-43.50) in Tanzania and USD 27.11 (CI: 26.54-27.68) in Zambia. When a 
minimum wage value was used as a proxy for lay-worker salaries, the intervention costs 
fell to USD 37.59 (CI: 35.15-40.02) and 45.78 (CI: 44.75 – 46.81) per person in Tanzania 
and Zambia respectively.  
 
 
DISCUSSION 
 
In this trial, just four short home visits conducted by lay-workers to provide adherence 
support combined with screening for cryptococcal meningitis led to a substantial 
reduction in mortality among HIV-infected patients initiating antiretroviral therapy with 
advanced disease. The death rate was about 30% less than that among individuals who 
did not receive this simple supportive package. These findings were robust to sensitivity 
analyses. The trial was large, integrated into normal health services (i.e. done under real 
life conditions), had a low loss to follow-up and the findings were consistent in both 
Tanzania and Zambia. 
 
The survival benefits from each component of our intervention are difficult to estimate 
precisely but we believe that the cryptococcal meningitis screening and the community 
support together resulted in the mortality reduction. We detected cryptococcal antigen 
in serum in 38 participants and offered pre-emptive fluconazole treatment to the 35 
participants in whom cryptococcal meningitis could not be confirmed. Only a few 
relatively small-scale clinical studies of cryptococcal infection have been done in Africa. 
A study from Cape Town suggested that individuals who are serum cryptococcal antigen 
positive have a very high risk of developing cryptococcal meningitis 33 and an earlier 
study from Uganda showed that antigenaemia preceded symptoms of cryptococcal 
meningitis by a median of 22 days 34. Among patients entering ART programmes with 
CD4 count <100 cells/μl who do not have any obvious signs of cryptococcal meningitis, 
the presence of antigenaemia has been associated with a much increased risk of 
mortality. In well-resourced clinical settings, mortality rates were over 6-fold higher in a 
study conducted in Uganda 35 and over a 3-fold higher in Cape Town 33. Both studies 
were retrospective and did not involve pre-emptive treatment as used in our study. The 
mortality rate among serum cryptococcal antigen positive individuals is lower in our 
study, which was integrated into a normal health care setting; but the comparison 
involves small numbers.  Finally, among 26 incident cases of cryptococcal antigenaemia 
in Uganda, whose CD4 count were <100 cells/μl, 5 out of 5 patients treated with ART 
alone died compared with 6/21 (29%) deaths among those treated with pre-emptive 
fluconazole and ART 36, although the data from Cape Town suggest that a proportion of 
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individuals starting on ART are able to clear asymptomatic infection through immune 
reconstitution 33.  
 
Taken together, the evidence suggests most of the participants who survived despite 
being serum cryptococcal antigen positive would have died in the absence of pre-
emptive antifungal treatment and that this component of the intervention contributed to 
about half of the mortality reduction observed in the intervention arm. Thus, serum 
cryptococcal antigen screening combined with pre-emptive fluconazole treatment is an 
effective strategy in reducing the high HIV-associated mortality in Africa and this 
strategy alone should be highly cost-effective in most settings 37, 38. It might be more 
effective if cryptococcal meningitis, as opposed to antigenaemia without meningitis, 
could be diagnosed and treated with amphotericin-based therapy rather than 
fluconazole 39 alone, but diagnosis of cryptococcal meningitis requires a lumbar 
puncture and in our study, three-quarters of the patients refused. Research is needed to 
understand the attitudes of both patients and caregivers to lumbar puncture and to 
determine the barriers to its acceptance, particularly in asymptomatic or minimally 
symptomatic infection; and to determine if meningitis can be predicted from the titre of 
antigenaemia in blood and treated with more potent antifungal combinations when 
antigenaemia is high.  
 
We found a large burden of TB at enrolment. We sought sputum samples irrespective of 
symptoms and the vast majority of participants provided these; more than a third 
diagnosed with TB did not report a cough; and the use of Xpert in addition to existing 
diagnostics doubled the number diagnosed. Implementing re-screening of TB after a few 
weeks proved a challenge for the health system. Zambia could not implement this but 
Tanzania did for about half of those in whom TB was not detected at enrolment. 
Consequently, the number of new TB cases detected was small and unlikely to have 
contributed to the reduction of all-cause mortality observed in the clinic plus 
community support arm.  
 
It is likely that a substantial proportion of the reduction in mortality – around a half - 
was the result of the lay-worker component which involved the provision of 
personalised adherence support in the community to study participants. Lay-workers 
proved effective in our earlier trial in Uganda 24, 25 but that trial was done in a largely 
poor rural setting with HIV services provided by a non-governmental organisation 
(NGO) and lay-workers provided home care throughout the 3-year follow-up. Here we 
evaluated a short intensive period of just 4-weeks in urban-based government clinics 
where access to care was much less of a barrier. The lay-workers had only about half the 
training as in Uganda and were less educated in order to keep the intervention costs 
low. Our findings suggest that this component of the intervention on its own is also a 
highly cost-effective strategy that could significantly enhance the impacts of ART 
programmes in Africa. Repeated adherence support could also be important for other 
groups of patients, such as those presenting with suspected treatment failure. In our 
trial, we did not observe a difference in reported adherence to ART between the two 
arms, but this was not surprising given the subjective nature of adherence measurement 
in Africa and elsewhere.  
 
These findings are supported by randomised trials showing improved virological 
suppression associated with peer support in Rakai, Uganda 40 and with 3-clinic-based 
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counselling sessions around the time of ART initiation in Nairobi, Kenya 41. The evidence 
is now probably sufficient to say that trained lay-workers, who are paid a salary, 
integrated into health systems and who work under the supervision of clinical staff are 
an effective cadre and that drug adherence support of patients in resource limited 
settings, particularly in the first few weeks of ART, is critical to improving patient 
outcomes. 
 
During the scale-up of ART in Africa, the emphasis has been to provide patients 
information before they initiate ART but the benefits of this strategy have never been 
established. This pre-ART period is the time when high rates of mortality 3-5 and loss 
from care 6, 7 can occur. We reduced this period by more than half and initiated ART at 
the patient’s second visit in both of the trial arms. Despite the reduced preparedness of 
patients, there appeared to be no adverse impacts on the rates of loss from care – this 
was 2.5% over 12 months – or on the overall mortality rate, which was broadly in line 
with that published from other African cohorts 24, 42, 43 even though our patients had 
presented with low CD4 counts or on reported adherence 44. These findings call into 
question the policy in most of Africa of a prolonged period of ART preparedness and 
suggest that rapid initiation of ART combined with support given following ART 
initiation would be more effective.  
 
The cost of our entire intervention varied between about $40 to $70 per participant 
depending on the scenario and the country. This one-off cost has to be balanced against 
annual life-long costs of ART of between $270 and $450 per patient 45. In a real-life scale 
up of the intervention, the costs could be considerably lower as lay-workers would likely 
be paid a lower salary than we had to pay to attract and train people quickly for trial 
purposes, they could visit more patients per day as patients would be less scattered than 
our trial participants, and the costs of the cryptococcal antigen test could fall. But even if 
the actual intervention cost were to remain at $70 per patient, the combined strategy is 
is likely to be highly cost-effective given the near 30% reduction in mortality. We also 
showed that ART can be initiated with fewer clinic visits and over a shorter time 
window, which will bring further cost savings and further reductions in mortality in ART 
programmes. Mortality rates among HIV-infected Africans entering ART programmes 
have remained stubbornly high during the pre-treatment period and for a few months 
following ART initiation 3-5, much higher than in high-income countries 2, and our 
findings point to a simple strategy that could narrow the disparities.  
 
In summary, this large trial has demonstrated that a simple intervention comprising the 
screening patients presenting to African health services with advanced disease for 
cryptococcal meningitis combined with a short period of community support from lay-
workers reduces mortality substantially.  
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Figure 1. Trial profile 
 
 
 
 
Note: Tz = Tanzania; Zm = Zambia  
Sought HIV care at 
clinic 9041 
(3697 Tz, 5344 Zm)
Randomised
1999 
(870 Tz, 1129 Zm)
Allocated to 
intervention arm 1001
(434Tz, 567 Zm)
Allocated to control 
arm 998
(436Tz, 562 Zm)
Died 109
Alive 781
Lost 22
Died 180
Alive 783
Lost 24
Assessed for eligibility 
3186
(1377 Tz, 1809 Zm)
Excluded 1187 (507 Tz, 680 Zm)
Needs admission 320
Lives outside clinic catchment 164
Moving away within 6 months 136
Not ART naive 165
Communication difficulties 26
Declined to participate 26
Reason unknown 350
Not assessed for eligibility 5855
CD4>100 before criteria change  697
CD4>200 after criteria change 4023
CD4 count currently missing 959
Sample haematolysed 72
CD4 instrument not working 65
CD4 not done 29
No blood sample obtained 8 
Already started ART 2
Received CrAg screen 
& ≥1 visit 912
Did not receive 
intervention: 89
No home visits 78
No CrAg screen 16
Did not receive        
intervention 987
Received 
intervention: 11
Home visits 4
CrAg screen 7
Died 0
Alive 11
Lost 0
Died 25
Alive 61
Lost 3
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Figure 2: Kaplan-Meier curves showing all-cause mortality in the clinic plus community 
support (CCS) and standard care arms i) overall, ii) among those who presented with 
CD4 count<50 /μl, iii) among those who presented with CD4 count≥50 /μl. Figure iv 
shows the mortality in those who were cryptococcal serum antigen positive versus 
those who were negative. The test was done in the clinic plus community support arm. 
 
 
 
i) overall  
 
ii) CD4 count<50 /μl  
 
  
  
iii) CD4 count≥50 /μl. iv) clinic plus community support arm 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
0
.0
0
0
.1
0
0
.2
0
0
.3
0
0
.4
0
P
ro
p
o
rt
io
n
 d
ie
d
998 869 834 811 794Standard care
1001 899 869 854 842CCS
Number at risk
0 3 6 9 12
Follow up (months)
Standard care
CCS
All
0
.0
0
0
.1
0
0
.2
0
0
.3
0
0
.4
0
P
ro
p
o
rt
io
n
 d
ie
d
393 326 311 295 284Standard care
377 315 302 298 292CCS
Number at risk
0 3 6 9 12
Follow up (months)
Standard care
CCS
CD4<50
0
.0
0
0
.1
0
0
.2
0
0
.3
0
0
.4
0
P
ro
p
o
rt
io
n
 d
ie
d
605 543 523 516 510Standard care
624 584 567 556 550CCS
Number at risk
0 3 6 9 12
Follow up (months)
Standard care
CCS
CD4 50+
0
.0
0
0
.2
5
0
.5
0
0
.7
5
1
.0
0
P
ro
p
o
rt
io
n
 d
ie
d
947 857 830 816 804CrAg -ve
38 27 25 24 24CrAg +ve 
Number at risk
0 3 6 9 12
Follow up (months)
CrAg -ve
CrAg +ve
 15 
Table 1. Participant characteristics at enrolment     
    Tanzania   Zambia  
  
Clinic plus community 
support 
Standard 
care  
Clinic plus community 
support Standard care 
Number enrolled  434 436  567 562 
       
Age, Median (IQR) years  38.0(32.0,45.0) 37.0(31.0,44.0) 35.0(30.0,41.0) 35.0(30.0,42.0) 
       
Sex, number female (%)  273(62.9) 268(61.5)  279(49.2) 257(45.7) 
       
WHO Clinical Stage, number (%)      
 1 33(7.6) 34(7.8)  218(38.4) 189(33.6) 
 2 47(10.8) 45(10.3)  98(17.3) 98(17.4) 
 3 251(57.8) 245(56.2)  240(42.3) 256(45.6) 
 4 103(23.7) 112(25.7)  11(1.9) 19(3.4) 
       
Body mass index (Kg/m2), median (IQR) 19.7(17.8,22.4) 19.8(17.6,22.6) 19.0(17.1,21.4) 18.8(16.8,21.2) 
       
CD4 count /μl,        
 <50 202(46.5) 217(49.8)  175(30.9) 176(31.3) 
 50-99 152(35.0) 131(30.0)  195(34.4) 183(32.6) 
 100-200 80(18.4) 88(20.2)  197(34.7) 203(36.1) 
       
 median (IQR) 53.0(22.0,89.0) 50.0(18.5,90.0) 79.0(41.0,128.0) 75.5(37.0,127.0) 
       
ART regimen,  number (%)¶       
 D4T, 3TC, NVP 0(0.0) 2(0.5)  0(0.0) 0(0.0) 
 D4T, 3TC, EFV 5(1.2) 3(0.7)  0(0.0) 0(0.0) 
 AZT, 3TC, NVP 38(8.8) 25(5.7)  1(0.2) 1(0.2) 
 AZT, 3TC, EFV 112(25.8) 139(31.9)  1(0.2) 0(0.0) 
 16 
 TDF, 3TC, EFV 181(41.7) 175(40.1)  1(0.2) 0(0.0) 
 ABC, 3TC, NVP 1(0.2) 0(0.0)  5(0.9) 7(1.2) 
 ABC, 3TC, EFV 6(1.4) 1(0.2)  16(2.8) 14(2.5) 
 TDF, FTC, EFV 80(18.4) 83(19.0)  511(90.1) 490(87.2) 
 TDF, FTC, NVP 0(0.0) 0(0.0)  2(0.4) 3(0.5) 
 Other 1(0.2) 1(0.2)  29(5.1) 47(8.4) 
 Never started ART 10(2.3) 7(1.6)  1(0.2) 0(0.0) 
       
Education level, number (%)*        
 None 80(18.4) 68(15.6)  4(1.6) 6(2.4) 
 Primary 292(67.3) 304(69.7)  101(39.8) 99(39.4) 
 Secondary 51(11.8) 55(12.6)  139(54.7) 141(56.2) 
 Tertiary 11(2.5) 9(2.1)  10(3.9) 5(2.0) 
       
Marital Status, number (%)*        
 Married 170(39.2) 187(42.9)  143(56.3) 138(55.0) 
 Cohabiting 18(4.1) 25(5.7)  3(1.2) 1(0.4) 
 Widowed 58(13.4) 29(6.7)  40(15.7) 30(12.0) 
 Separated/divorced 135(31.1) 122(28.0)  31(12.2) 45(17.9) 
  Never married 53(12.2) 73(16.7)  37(14.6) 37(14.7) 
 
Footnotes: 
¶: 10 participants died, 5 withdrew and 2 were lost-to-follow-up after randomisation and before ART could be initiated and one person 
refused to go onto ART. These 18 participants were distributed as 11 in the clinic plus community support arm and 7 in the standard 
care arm. They were retained in the intention-to-treat analyses.  
* These data were collected from only 4 of the 6 clinics.  
Note:  In Zambia the median (IQR) time from first presentation to ART initiation was 14(11,19) days in the clinic plus community 
support arm compared with 14 (12,21) days in the standard care arm. In Tanzania these were 11 (8,19) days compared with 13(8,21) 
days respectively. 
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Table 2. Number of participants diagnosed with tuberculosis and cryptococcal 
meningitis at trial enrolment 
  
 
Clinic plus community 
support 
Standard care 
 
 Tanzania Zambia Tanzania Zambia 
     
Number of participants 434 567 436 562 
     
On anti-TB treatment at 
enrolment, n (%) 72 (16.6) 83 (14.6) 70 (16.1) 100 (17.8) 
     
Newly diagnosed with 
active TB at enrolment by 
any method, n (%)  42 (9.7) 47 (8.3) 49 (11.2) 51 (9.1) 
     
 
Newly diagnosed by 
sputum smear, 
clinical symptoms 
and chest x-ray 28 (66.7) 21/47 (44.7) 23 (46.9) 25 (49.0) 
     
 
Diagnosed on the 
basis of Xpert either 
alone or in 
combination with 
sputum smear, 
clinical symptoms or 
chest x-ray 14 (33.3) 23 (48.9) 26 (53.1) 25 (49.0) 
     
 
Diagnosed on the 
basis of culture 0 3 (6.4) 0 1 (2.0) 
     
     
Cryptococcal antigen 
positive at enrolment, n 
(%)† 22/434  (5.1) 16/567 (2.8) - - 
     
Agreed to have a lumbar 
puncture, n (%) 5/22 (22.7) 4/16 (25.0) - - 
     
CSF positive for 
cryptococcus, n(%) 0 /5 (0) 3/4 (75.0) - - 
     
 
† 355 in Tanzania and 373 in Zambia had CD4 count≤100/ μl in the clinic plus community support 
arm. 
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Table 3: Rates of all-cause mortality and first hospitalisation over 12 months duration 
following initiation of antiretroviral therapy. 
  
 Clinic plus community support Standard Care   
 Events PYO Rate (95% CI) Events PYO Rate (95% CI) RR (95% CI) p-
value 
Mortality         
All  134 877 15.3(12.9,18.1) 180 843 21.3(18.4,24.7) 0.72(0.57,0.90) 0.004 
Tanzania 66 370 17.9(14.0,22.7) 87 359 24.2(19.6,29.9) 0.74(0.54,1.01) 0.073 
Zambia 68 507 13.4(10.6,17.0) 93 484 19.2(15.7,23.5) 0.70(0.51,0.95) 0.027 
         
Hospitalisation*        
All  77 864 8.9(7.1,11.1) 73 836 8.7(6.9,11.0) 1.02(0.74,1.41) 0.820 
Tanzania 26 364 7.1(4.9,10.5) 32 358 8.9(6.3,12.6) 0.80(0.48,1.34) 0.431 
Zambia 51 500 10.2(7.8,13.4) 41 478 8.6(6.3,11.6) 1.19(0.79,1.80) 0.366 
 
* Only first hospitalisation included. There were 155 hospitalisations in total (4 
participants in the clinic and community support arm and one on standard care were 
hospitalised twice).   
 
Note: The effect sizes were unchanged after adjusting for study site, age, sex, baseline 
CD4 count (rate ratio 0.74, 95% CI 0.59, 0.92), assuming that all participants lost from 
care had died (rate ratio 0.75, 95% CI 0.61, 0.92), or assuming that only those lost in the 
first 28 days had died (rate ratio 0.69, 95% CI 0.56, 0.86).  
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Table 4: Number of participants reporting perfect adherence *  to antiretroviral 
therapy during the previous 28 days, as measured at six and 12 monthly patient 
reviews.  
 
 
Clinic and 
community 
support Standard care   
 % (n) % (n) Rate ratio p-value 
All     
Month 6 review 90.1(421/467) 86.2(375/435) 1.05(1.00,1.10) 0.068 
Month 12 review 88.6(451/509) 89.2(429/481) 0.99(0.95,1.04) 0.770 
     
Tanzania     
Month 6 review 86.1(180/209) 80.2(162/202) 1.07(0.98,1.17) 0.111 
Month 12 review 89.1(236/265) 90.4(226/250) 0.99(0.93,1.04) 0.616 
     
Zambia     
Month 6 review 93.4(241/258) 91.4(213/233) 1.02(0.97,1.08) 0.407 
Month 12 review 88.1(215/244) 87.9(203/231) 1.00(0.94,1.07) 0.937 
 
* perfect adherence was defined as not missing a single pill in the last 28 days. 
Adherence was measured by patient interview. 
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Table 5. Mortality rates among cryptococcal serum antigen positive and negative participants in the clinic plus 
community support arm. 
 
   
 Serum antigen positive Serum antigen negative 
 
  
 No. of deaths 
(%) 
Rate /100 person 
years (95% CI) 
No. of deaths 
(%) 
Rate /100 person 
years (95% CI) 
Rate ratio (95% CI) 
Unadjusted 
Rate ratio (95% CI) 
Adjusted * 
       
All participants 12/38 
(31.6) 
46.3 
(26.3, 81.5) 
120/947  
(12.7) 
14.3 
(12.0, 17.1) 
3.23 
(1.78, 5.84) 
2.90 
(1.60, 5.26) 
       
Participants with  
<100 CD4/μl 
11/33 
(33.3) 
50.1  
(27.8, 90.5)   
101/684  
(14.8) 
17 
(14.0, 20.7) 
2.95  
(1.58, 5.49) 
2.87 
(1.54, 5.37) 
       
* adjusted for CD4 count, age, sex, country 
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